The unique methylerythritol phosphate pathway for isoprenoid biosynthesis is essential in most bacterial pathogens. The first enzyme in this pathway, 1-deoxy-D-xylulose 5-phosphate (DXP) synthase, catalyzes a distinct thiamin diphosphate (ThDP)-dependent reaction to form DXP from D-glyceraldehyde 3-phosphate (D-GAP) and pyruvate and represents a potential anti-infective drug target. We have previously demonstrated that the unnatural bisubstrate analog, butylacetylphosphonate (BAP), exhibits selective inhibition of Escherichia coli DXP synthase over mammalian ThDP-dependent enzymes. Here, we report the selective inhibition by BAP against recombinant DXP synthase homologs from Mycobacterium tuberculosis, Yersinia pestis and Salmonella enterica. We also demonstrate antimicrobial activity of BAP against both Gram-negative and Gram-positive strains (including E. coli, S. enterica and Bacillus anthracis), and several clinically isolated pathogens. Our results suggest a mechanism of action involving inhibition of DXP synthase and show that BAP acts synergistically with established antimicrobial agents, highlighting a potential strategy to combat emerging resistance in bacterial pathogens.
独特的甲基
赤藓醇磷酸通路对于
异戊二烯的
生物合成在大多数细菌病原体中是必需的。该通路中的第一个酶—
1-脱氧-D-木酮糖-5-
磷酸(DXP)合酶,催化一个特异的
硫胺素焦磷酸(ThDP)依赖的反应,由D-
甘油醛-3-
磷酸(D-GAP)和
丙酮酸形成DXP,是潜在的抗感染药物靶标。我们之前已经证明,非天然双底物类似物丁基
乙酰磷酸盐(
BAP)对大肠杆菌DXP合酶具有选择性抑制作用,而对哺乳动物ThDP依赖性酶无明显影响。本文报道了
BAP对结核分枝杆菌、鼠疫耶尔森菌和肠炎沙门氏菌的
重组DXP合酶同源物的选择性抑制作用。我们还证明了
BAP对革兰氏阴性和阳性菌株(包括大肠杆菌、肠炎沙门氏菌和
炭疽芽胞杆菌)以及几种临床分离的病原体具有抗菌活性。我们的研究结果表明其作用机制涉及DXP合酶的抑制,并且
BAP与已建立的抗菌药物具有协同作用,突出了一种对抗细菌病原体新兴耐药性的潜在策略。